Filing Details
- Accession Number:
- 0001209191-23-025669
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-04-26 16:11:24
- Reporting Period:
- 2023-04-24
- Accepted Time:
- 2023-04-26 16:11:24
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1786205 | Arcellx Inc. | ACLX | Biological Products, (No Disgnostic Substances) (2836) | 472855917 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1789632 | Christopher Heery | C/O Arcellx, Inc. 25 West Watkins Mill Road, Suite A Gaithersburg MD 20878 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-04-24 | 10,000 | $6.28 | 21,692 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2023-04-24 | 10,000 | $15.00 | 31,692 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-04-24 | 20,000 | $40.00 | 11,692 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2023-04-24 | 10,000 | $0.00 | 10,000 | $6.28 |
| Common Stock | Stock Option (right to buy) | Disposition | 2023-04-24 | 10,000 | $0.00 | 10,000 | $15.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 240,623 | 2031-06-09 | No | 4 | M | Direct | |
| 224,205 | 2032-02-03 | No | 4 | M | Direct |
Footnotes
- The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on June 30, 2022.
- Represents the weighted average share price of an aggregate total of 20,000 shares sold in the price range of $40.00 to $40.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Shares issued pursuant to the Issuer's 2017 Equity Incentive Plan (the "2017 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2017 Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021.
- Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one forty-eighth (1/48th) of the shares subject to the option will vest each month following Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over four (4) years. "Equity Grant Date" shall mean February 3, 2022.
Billionaire Hedge Funds
